Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, warned that cuts to public health funding in a potential debt ceiling deal between the Biden administration and congressional Republicans could have dire consequences for HIV testing, case investigation, and treatment. “This will result in new infections, more people living with HIV and the need to provide lifetime care and treatment,” Schmid said.
“It appears that our investments in HIV prevention are providing some positive results, but the persistent high number of new diagnoses and the low usage of PrEP among the communities most impacted by HIV point to the need for increased resources, particularly for a national PrEP program,” Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, said in a statement. “While there have been some increases, they have not been at the level needed to put the U.S. on a path to end HIV.”
“Copay accumulator programs are manifestly unlawful and endanger millions of people living with HIV, hepatitis, and other chronic conditions who rely on copay assistance to afford their medicines,” Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, said in a statement as plaintiffs filed their May 1 brief.
A yet-to-be-finalized debt ceiling deal between Democrats and Republicans could mean tens of billions of dollars of cuts to public health funding for testing, case investigation and treatment of HIV and other STDs. “This will result in new infections, more people living with HIV and the need to provide lifetime care and treatment,” warned Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.
“It appears that our investments in HIV prevention are providing some positive results, but the persistent high number of new diagnoses and the low usage of PrEP among the communities most impacted by HIV point to the need for increased resources, particularly for a national PrEP program,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.